IDEXX LABORATORIES INC /DE Net Change in Cash
IDEXX LABORATORIES INC /DE (IDXX) reported Net Change in Cash of $16.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $20.46M.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$124.30M.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$56.50M.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$1.18M, a 101.96% decline year-over-year.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$108.20M.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$165.67M, a 148.53% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $341.39M.
- IDEXX LABORATORIES INC /DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$31.91M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.86M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $20.46M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$108.20M 10-K · filed 2026-02-20 | |||
| 2025-09-30 | -$80.10M 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | -$123.67M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | -$124.30M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$165.67M 10-K · filed 2026-02-20 | |||
| 2024-09-30 | -$145.30M 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | -$52.34M 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | -$56.50M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $341.39M 10-K · filed 2026-02-20 | |||
| 2023-09-30 | $219.15M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $20.29M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$1.18M 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | -$31.91M 10-K · filed 2025-02-21 | |||
| 2022-09-30 | -$45.28M 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | -$30.09M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | $60.16M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | -$239.47M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | -$238.72M 10-Q · filed 2022-11-01 | |||
| 2021-06-30 | -$151.79M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$32.77M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $293.60M 10-K · filed 2023-02-16 | |||
| 2020-09-30 | $85.26M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $14.97M 10-Q · filed 2021-07-30 | |||
| 2020-03-31 | -$8.93M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$33.47M 10-K · filed 2022-02-16 | |||
| 2019-09-30 | -$19.80M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | -$12.95M 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | -$7.18M 10-Q · filed 2020-04-30 | |||
| 2018-12-31 | -$63.88M 10-K · filed 2021-02-12 | |||
| 2018-09-30 | -$40.80M 10-Q · filed 2019-10-31 | |||
| 2018-06-30 | -$13.12M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | -$28.45M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $32.77M 10-K · filed 2020-02-14 | |||
| 2017-09-30 | $14.12M 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | $11.07M 10-Q · filed 2018-08-01 | |||
| 2017-03-31 | $5.51M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |